CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Ipilimumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01611558
NCT01611558Phase 2Completed
CompareCT.gov

A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects

Bristol-Myers Squibb·interventional·Posted Jun 5, 2012·Updated Jul 13, 2020

In Brief

A Phase 2 clinical trial evaluating Ipilimumab for Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line. Completed, enrolled 40 participants across 17 sites.

Detailed Summary

To assess the incidence of drug-related adverse events of Grade 3 or higher and the overall response associated with ipilimumab treatment

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlatinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 5, 2012
Enrollment StartAug 21, 2012
Primary CompletionNov 3, 2014
Study CompletionJul 3, 2019
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 14.1 years ago

Interventions

Ipilimumabbiological